<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01301586</url>
  </required_header>
  <id_info>
    <org_study_id>11022006</org_study_id>
    <nct_id>NCT01301586</nct_id>
  </id_info>
  <brief_title>A Novel Combination Oral Agent to Treat Acne Vulgaris</brief_title>
  <official_title>A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF A NOVEL ORAL ACNE TREATMENT FOR THE TREATMENT OF ACNE VULGARIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nexgen Dermatologics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nexgen Dermatologics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a novel, combination product for the treatment of
      acne vulgaris in females
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean number of Inflammatory Lesions on the face at the beginning and end of treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of inflammatory lesions will be counted by a trained investigator at the beginning and end of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean number of Comedones will be evaluated at the beginning and end of treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>A trained investigator will count the number of comedones at the beginning and end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>ACNE VULGARIS</condition>
  <arm_group>
    <arm_group_label>Oral antibiotic plus soy extract</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral antibiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline and S-equol</intervention_name>
    <description>Oral doxycycline and s-equol twice a day</description>
    <arm_group_label>Oral antibiotic plus soy extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>ORAL DOXYCYCLINE TWICE A DAY</description>
    <arm_group_label>Oral antibiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy females 13 years of age or older

          -  Non-pregnant, non-lactating females

          -  Signed written informed consent form

          -  Must be able to understand and be willing to follow all study instructions

          -  Have a clinical diagnosis of acne vulgaris

        Exclusion Criteria:

          -  Female subjects who are pregnant or nursing

          -  Any concomitant dermatologic condition that may affect outcome measures

          -  Concurrent use of any other medication to treat acne vulgaris

          -  Have a history or clinical evidence of any other active acute or chronic medical
             disease or condition considered by the principal investigator as unsuitable for the
             study

          -  Are currently using any other investigational agent or device

          -  Have participated in any other clinical study within 90 days prior to enrollment

          -  Employees or family members of sponsor or research site
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua M Berlin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Protocol, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>H G Berlin, ESQ</last_name>
    <phone>561-739-5252</phone>
    <email>garyberlin17@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Palos Verdes Dermatology Associates</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Fein, MD</last_name>
      <phone>310-541-7800</phone>
    </contact>
    <investigator>
      <last_name>HOWARD FEIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Berlin Center</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33437</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H G Berlin, ESQ</last_name>
      <phone>561-739-5252</phone>
      <email>garyberlin17@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Joshua M Berlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2011</study_first_submitted>
  <study_first_submitted_qc>February 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <last_update_submitted>February 18, 2011</last_update_submitted>
  <last_update_submitted_qc>February 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>H. Gary Berlin</name_title>
    <organization>Nexgen Dermatologics, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Equol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

